Pilot Study of a Catheter-based Ultrasound Hyperthermia System
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cervical Cancer, Cervical Cancer, Cancer, Cancer, Infectious Disease, Women's Studies |
| Therapuetic Areas: | Immunology / Infectious Diseases, Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/26/2019 |
| Start Date: | April 2009 |
| End Date: | September 2020 |
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above
normal body temperature. Ultrasound energy may be able to kill tumor cells by heating up the
tumor cells without affecting the surrounding tissue. Implant radiation therapy uses
radioactive material placed directly into or near a tumor to kill tumor cells. Giving
ultrasound hyperthermia therapy after implant radiation therapy may kill more tumor cells.
PURPOSE: This clinical trial is studying ultrasound hyperthermia therapy to see how well it
works after implant radiation therapy in treating patients with Stage III/IV cancer of the
cervix or prostate cancer with a rising prostate specific antigen (PSA) after prior local
therapy.
normal body temperature. Ultrasound energy may be able to kill tumor cells by heating up the
tumor cells without affecting the surrounding tissue. Implant radiation therapy uses
radioactive material placed directly into or near a tumor to kill tumor cells. Giving
ultrasound hyperthermia therapy after implant radiation therapy may kill more tumor cells.
PURPOSE: This clinical trial is studying ultrasound hyperthermia therapy to see how well it
works after implant radiation therapy in treating patients with Stage III/IV cancer of the
cervix or prostate cancer with a rising prostate specific antigen (PSA) after prior local
therapy.
OUTLINE: Patients undergo standard high-dose rate (HDR) brachytherapy. Approximately 2 hours
after brachytherapy, patients undergo catheter-based ultrasound hyperthermia therapy over 60
minutes. Treatment with HDR brachytherapy and hyperthermia therapy repeats within 1-3 weeks.
Patients may then undergo 2 additional standard HDR brachytherapy sessions.
After completion of study therapy, patients are followed at 1 and 3 months.
after brachytherapy, patients undergo catheter-based ultrasound hyperthermia therapy over 60
minutes. Treatment with HDR brachytherapy and hyperthermia therapy repeats within 1-3 weeks.
Patients may then undergo 2 additional standard HDR brachytherapy sessions.
After completion of study therapy, patients are followed at 1 and 3 months.
Inclusion Criteria:
Patients who are to be given HDR brachytherapy for treatment of solid tumor of the
following:
- Cervical cancer Stage III or IV OR
- Prostate cancer (with rising prostate specific antigen after prior local therapy)
Age ≥18 years
Eligible for brachytherapy as determined per clinical standard of care.
Ability to give written informed consent and willingness to comply with the requirements of
the protocol
Exclusion Criteria:
Patients who are not candidates for HDR brachytherapy
Any condition that compromises compliance with the objectives and procedures of this
protocol, as judged by the principal investigator
We found this trial at
1
site
1600 Divisadero Street
San Francisco, California 94115
San Francisco, California 94115
888.689.8273
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
Click here to add this to my saved trials
